biostudies-literatureMonasta LItalian Ministry of Health11498https://www.ebi.ac.uk/biostudies/studies/S-EPMC12691889biostudies-literatureUnknown26(23)Endometrial cancers (ECs) are mainly adenocarcinomas arising from the uterine endometrium. In this work, we employed data-independent acquisition (DIA) mass spectrometry (MS)-based label-free quantification (LFQ-MS) proteomics to analyze the proteome of tissue washings collected from 25 control (CTRL) subjects, 25 patients with low-grade type 1 endometrial cancer (EC), and 24 patients with high-grade type 1 EC. Following quantification and statistical analysis, we identified 42 proteins able to discriminate CTRL from EC patients, and 151 proteins differentiating high-grade EC cases from low-grade EC cases. Notably, <i>PRRC2A</i> and <i>SYDE2</i> effectively distinguished both EC patients from controls and advanced EC cases from low-grade EC cases. Validation by Western blot analysis in an International journal of molecular sciencesData-Independent Acquisition (DIA)-Based Proteomics for the Identification of Biomarkers in Tissue Washings of Endometrial Cancer.PMC126918895x1000 SD 18\19Monasta LKharrat FCapaci VAloisio MBalasan NUra BRomano FGolino VCiampechini MRicci GConti ALicastro DDi Lorenzo GCampiglia PfalseData-Independent Acquisition (DIA)-Based Proteomics for the Identification of Biomarkers in Tissue Washings of Endometrial Cancer.Endometrial cancers (ECs) are mainly adenocarcinomas arising from the uterine endometrium. In this work, we employed data-independent acquisition (DIA) mass spectrometry (MS)-based label-free quantification (LFQ-MS) proteomics to analyze the proteome of tissue washings collected from 25 control (CTRL) subjects, 25 patients with low-grade type 1 endometrial cancer (EC), and 24 patients with high-grade type 1 EC. Following quantification and statistical analysis, we identified 42 proteins able to discriminate CTRL from EC patients, and 151 proteins differentiating high-grade EC cases from low-grade EC cases. Notably, <i>PRRC2A</i> and <i>SYDE2</i> effectively distinguished both EC patients from controls and advanced EC cases from low-grade EC cases. Validation by Western blot analysis in an 2025-01-01T00:00:00Z2025 Nov2026-05-26T14:03:39.574Z2026-05-24T03:11:45.521ZS-EPMC126918894137365110.3390/ijms262311498